Published in J Gastroenterol on February 24, 2012
Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol (2013) 0.81
Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liver Cancer (2014) 0.80
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. Drug Des Devel Ther (2014) 0.80
Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J (2015) 0.79
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol (2013) 0.76
Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia. Gastroenterol Res Pract (2015) 0.75
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol (2016) 0.75
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Hepatitis B genotypes and the response to interferon therapy. J Hepatol (2000) 2.97
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol (2002) 2.57
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods (1999) 1.70
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology (1992) 1.52
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol (2004) 1.42
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology (1997) 1.28
Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol (2002) 1.06
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology (1997) 1.02
Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol (1992) 0.98
Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol (1990) 0.92
Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Methods (2006) 0.92
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol (2007) 0.79
Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antiviral Res (2009) 0.78
A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels. J Gastroenterol (1996) 0.77
Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients. Hepatol Res (2002) 0.77
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Mapping human genetic diversity in Asia. Science (2009) 7.40
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell (2009) 4.52
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell (2010) 4.21
Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology (2002) 3.79
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol (2010) 3.51
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Nature and duration of growth factor signaling through receptor tyrosine kinases regulates HSV-1 latency in neurons. Cell Host Microbe (2010) 2.65
Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol (2005) 2.44
Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet (2006) 2.41
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology (2013) 2.36
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet (2011) 2.33
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
Effect of postmenopausal status and age at menopause on type 2 diabetes and prediabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 17 (TOPICS 17). Diabetes Care (2013) 2.15
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
The origin and evolution of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol (2005) 2.09
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A large variation in the rates of synonymous substitution for RNA viruses and its relationship to a diversity of viral infection and transmission modes. Mol Biol Evol (2004) 2.07
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Early outcome of folding mitral valve repair technique without resection for mitral valve prolapse in 60 patients. J Thorac Cardiovasc Surg (2012) 2.06
Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol (2005) 1.94
Reliabilities of identifying positive selection by the branch-site and the site-prediction methods. Proc Natl Acad Sci U S A (2009) 1.94
HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology (2002) 1.92
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology (2009) 1.83
Transcriptional interferences in cis natural antisense transcripts of humans and mice. Genetics (2007) 1.79
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol (2008) 1.76